The FDA said it found several manufacturing problems at Amylin Pharmaceuticals' facility in West Chester, Ohio, during a December inspection. "We've addressed these findings in previous public statements, indicating that we believe these observations are addressable," said a spokeswoman for Amylin. The agency was scheduled to decide by Friday whether to approve a once-weekly formulation of Byetta, a Type 2 diabetes drug developed by Amylin and Eli Lilly and Co.

Full Story:

Related Summaries